FDA working on pattern recognition model that could ID other heparin contaminants
This article was originally published in The Gold Sheet
Executive Summary
FDA's Division of Pharmaceutical Analysis is seeking contract support to develop a multivariate mathematical model that could tell whether heparin samples contain low levels of dermatan sulfate, a common impurity, oversulfated chondroitin sulfate, an economically motivated adulterant, or other oversulfated glucosaminoglycans that the division prepares or purchases. There has been speculation that the miscreants who contaminated heparin API with OSCS might try to do it with other substances. The FDA study will use heparin nuclear magnetic resonance imaging spectra from more than 150 heparin API samples tainted with varying levels of OSCS and dermatan sulfate, plus other sample data to "determine if pattern recognition models are capable of discriminating low levels of OSCS and other contaminants in heparin sodium," FDA said
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.